TopiVert's Series B Round

TopiVert raised a round of funding on January 03, 2014.

TopiVert is developing topical medicines for inflammatory diseases of the eye and gut. The company has licensed NSKI (narrow spectrum kinase inhibitor) related intellectual property from RespiVert for…

Articles about TopiVert's Series B Round: